Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Metastatic Colorectal Cancer

September 10, 2015

Join Chloe Atreya, MD, PhD and Alan P. Venook, MD from UCSF Helen Diller Family Comprehensive Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to metastatic colorectal cancer (mCRC).

The management of mCRC involves a continuum of care in which patients are exposed sequentially to a variety of active agents either in combinations or as single agents. The choice of therapy is based on the goals of treatment (i.e. eradication of micrometastases in resectable patients, tumor shrinkage to obtain resectability, slowing of disease in unresectable patients), the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, and the mutational status of the tumor. In discussing treatment options with patients with mCRC, clinicians need to consider the goals of therapy, the different efficacy and toxicity profiles of the drugs, the patient’s previous treatment history, the relevant tumor markers, and patient preferences. Clinicians must be aware of new data regarding extended RAS testing as well as the combination of cetuximab with FOLFOX in different mCRC settings to effectively lead these conversations.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Explain the importance of extended RAS testing and other considerations for selecting systemic therapy in patients with metastatic colorectal cancer
  • Summarize emerging evidence related to the combination of FOLFOX with cetuximab in different settings of metastatic colorectal cancer
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
09/08/2015
Course expires: 
11/02/2015
Event starts: 
09/10/2015 - 1:00pm
Event ends: 
09/10/2015 - 2:00pm
Cost:
$0.00

Chloe Atreya, MD, PhD
UCSF Helen Diller Family Comprehensive Cancer Center

Alan P. Venook, MD
UCSF Helen Diller Family Comprehensive Cancer Center

This activity is approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided. View complete accreditation information

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician

Accreditation Period

Course opens: 
09/08/2015
Course expires: 
11/02/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing